Mirogabalin, a novel α₂δ ligand, is not a substrate of LAT1, but of PEPT1, PEPT2, OAT1, OAT3, OCT2, MATE1 and MATE2-K

References

• Alles SRA, Gomez K, Moutal A, Khanna R. 2020. Putative roles of SLC7A5 (LAT1) transporter in pain. Neurobiol Pain. 8(8):100050.
   PubMedGoogle Scholar
• Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. 2019. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig. 10(5):1299–1306.
   PubMed Web of Science ®Google Scholar
• Brodie BB, Hogben CAM. 1957. Some physico-chemical factors in drug action. J Pharm Pharmacol. 9(6):345–380.
   PubMed Web of Science ®Google Scholar
• Brown K, Mendell J, Ohwada S, Hsu C, He L, Warren V, Dishy V, Zahir H. 2018. Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: results from phase 1 studies. Pharmacol Res Perspect. 6(5):e00418.
   PubMed Web of Science ®Google Scholar
• Deguchi T, Kusuhara H, Takadate A, Endou H, Otagiri M, Sugiyama Y. 2004. Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney Int. 65(1):162–174.
   PubMed Web of Science ®Google Scholar
• Domon Y, Arakawa N, Inoue T, Matsuda F, Takahashi M, Yamamura N, Kai K, Kitano Y. 2018. Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the a2d subunit of voltage-gated calcium channels. J Pharmacol Exp Ther. 365(3):573–582.
   PubMed Web of Science ®Google Scholar
• Goins AE, Gomez K, Ran D, Afaghpour-Becklund M, Khanna R, Alles SRA. 2022. Neuronal allodynic mechanisms of Slc7a5 (LAT1) in the spared nerve injury rodent model of neuropathic pain. Pflugers Arch Eur J Physiol. 474(4):397–403.
   PubMed Web of Science ®Google Scholar
• Hasannejad H, Takeda M, Taki K, Shin HJ, Babu E, Jutabha P, Khamdang S, Aleboyeh M, Onozato ML, Tojo A, et al. 2004. Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 308(3):1021–1029.
   PubMed Web of Science ®Google Scholar
• Hogben CAM, Tocco DJ, Brodie BB, Schanker LS. 1959. On the mechanism of intestinal absorption of drugs. J Pharmacol Exp Ther. 125(4):275–282.
   PubMed Web of Science ®Google Scholar
• Iwama R, Sato T, Sakurai K, Takasuna K, Ichijo T, Furuhama K, Satoh H. 2014. Estimation of glomerular filtration rate in cynomolgus monkeys (Macaca fascicularis). J Vet Med Sci. 76(10):1423–1426.
   PubMed Web of Science ®Google Scholar
• Jansen M, Warrington S, Dishy V, Ohwada S, Johnson L, Brown K, Ishizuka H. 2018. A randomized, placebo-controlled, double-blind study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and repeated doses of mirogabalin in healthy Asian volunteers. Clin Pharmacol Drug Dev. 7(6):661–669.
   PubMed Web of Science ®Google Scholar
• Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. 1998. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 273(37):23629–23632.
   PubMed Web of Science ®Google Scholar
• Kato J, Matsui N, Kakehi Y, Murayama E, Ohwada S, Sugihara M. 2019. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain. 160(5):1175–1185.
   PubMed Web of Science ®Google Scholar
• Kitano Y, Kai K, Yamamura N, Yoshiba S, Kuroha M. 2019. Pharmacological, pharmacodynamics, and clinical profile of mirogabalin besylate (Tarlige® tablets 2.5 mg, 5 mg, 10 mg, 15 mg). Folia Pharmacol Jpn. 154(6):352–361.
   PubMedGoogle Scholar
• Koepsell H. 2020. Organic cation transporters in health and disease. Pharmacol Rev. 72(1):253–319.
   PubMed Web of Science ®Google Scholar
• Lin JH, Los LE, Ulm EH, Duggan DE. 1987. Urinary excretion kinetics of famotidine in rats. Drug Metab Dispos. 15(2):212–216.
   PubMed Web of Science ®Google Scholar
• Orlando R, Floreani M, Padrini R, Palatini P. 1998. Determination of inulin clearance by bolus intravenous injection in healthy subjects and ascitic patients: equivalence of systemic and renal clearances as glomerular filtration markers. Br J Clin Pharmacol. 46(6):605–609.
   PubMed Web of Science ®Google Scholar
• Rubio-Aliaga I, Daniel H. 2008. Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica. 38(7–8):1022–1042.
   PubMed Web of Science ®Google Scholar
• Shaheen A, Alam SM, Azam F, Khan M, Ahmad Saleem S, Liaquat A, Mumtaz S. 2021. Influence of single nucleotide polymorphism of LAT1 on therapeutic response to gabapentinoids in Pakistani patients with neuropathic pain. Basic Clin Pharmacol Toxicol. 128(3):503–510.
   PubMed Web of Science ®Google Scholar
• Shen H, Lai Y, Rodrigues AD. 2017. Minireview. Organic anion transporter 2: an enigmatic human solute carrier. Drug Metab Dispos. 45(2):228–236.
   PubMed Web of Science ®Google Scholar
• Su TZ, Feng MR, Weber ML. 2005. Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells. J Pharmacol Exp Ther. 313(3):1406–1415.
   PubMed Web of Science ®Google Scholar
• Tachibana M, Yamamura N, Atiee GJ, Hsu C, Warren V, He L, Dishy V, Zahir H. 2018. Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: a phase 1, randomized, open-label, drug-drug interaction study. Br J Clin Pharmacol. 84(10):2317–2324.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Nishimura T, Higuchi K, Noguchi S, Tega Y, Kurosawa T, Deguchi Y, Tomi M. 2018. Transport of pregabalin via L-type amino acid transporter 1 (SLC7A5) in human brain capillary endothelial cell line. Pharm Res. 35(12):246.
   PubMed Web of Science ®Google Scholar
• Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K. 2007. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H+-organic cation antiporters. Biochem Pharmacol. 74(2):359–371.
   PubMed Web of Science ®Google Scholar
• Terada T, Irie M, Okuda M, Inui K. 2004. Genetic variant arg57his in human H+/peptide cotransporter 2 causes a complete loss of transport function. Biochem Biophys Res Commun. 316(2):416–420.
   PubMed Web of Science ®Google Scholar
• The International Transporter Consortium. 2010. Membrane transporters in drug development. Nat Rev Drug Discov. 9(3):215–236.
   PubMed Web of Science ®Google Scholar
• Uwai Y, Saito H, Hashimoto Y, Inui KI. 2000. Interaction and transport of thiazide diuretics, loop diuretics and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 295(1):261–265.
   PubMed Web of Science ®Google Scholar
• Verrey F, Meier C, Rossier G, Kuhn LC. 2000. Glycoprotein-associated amino acid exchangers: broadening the range of transport specificity. Pflugers Arch. 440(4):503–512.
   PubMed Web of Science ®Google Scholar
• Watanabe C, Kato Y, Ito S, Kubo Y, Sai Y, Tsuji A. 2005. Na+/H+ exchanger 3 affects transport property of H+/oligopeptide transporter 1. Drug Metab Pharmacokinet. 20(6):443–451.
   PubMedGoogle Scholar
• Wen J, Luo J, Huang W, Tang J, Zhou H, Zhang W. 2015. The pharmacological and physiological role of multi-resistant protein 4. J Pharmacol Exp Ther. 354(3):358–375.
   PubMed Web of Science ®Google Scholar
• Yamamura N, Mendel-Harary J, Brown K, Uchiyama M, Urasaki Y, Takahashi M, Warren V, Vashi V. 2021. Metabolism, excretion, and pharmacokinetics of [14C]mirogabalin, a novel α2δ ligand, in healthy volunteers following oral administration. Xenobiotica. 51(5):549–563.
   PubMed Web of Science ®Google Scholar
• Yamamura N, Uchiyama M, Takahashi M, Honda T, Nishiya Y. 2022. Pharmacokinetics and metabolism of mirogabalin, a novel α2δ ligand, in rats and monkeys. Xenobiotica. 52(1):54–64.
   PubMed Web of Science ®Google Scholar
• Yan R, Zhao X, Lei J, Zhou Q. 2019. Structure of the human LAT1-4F2hc heteromeric amino acid transporter complex. Nature. 568(7750):127–130.
   PubMed Web of Science ®Google Scholar
• Zolk O, Solbach TF, König J, Fromm MF. 2009. Functional characterization of the human organic cation transporter 2 variant p.270ala > ser. Drug Metab Dispos. 37(6):1312–1318.
   PubMed Web of Science ®Google Scholar